Home » FDA APPROVES NOVARTIS' VERSION OF TOPROL-XL
FDA APPROVES NOVARTIS' VERSION OF TOPROL-XL
Novartis, the world's second-largest generic drugmaker, won FDA approval for its version of AstraZeneca's Toprol-XL 25 mg hypertension drug.
AstraZeneca sold $1.7 billion worth of the drug in 2005, and the 25-mg dose represents about 20 percent of the drug's sales. Toprol-XL is AstraZeneca's third-best selling drug. The company is appealing a U.S. court loss over the patent.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May